IOPtima Reports Successful Long-Term Results in the Use of its Laser System for Treatment of Glaucoma

May 8, 2009

IOPtima, the Israeli developer of a laser-based surgical device for reducing intra ocular pressure (IOP) for the treatment of glaucoma, successfully completed and analyzed the results of its first 12-month follow-up period of human clinical trials conducted in Mexico and India.

IOPtima’s laser-based technology enables eye surgeons to perform a simple and safe surgery and reduce IOP without penetrating the eye membrane.

Study results showed the following results:

  • The combined results of the study in Mexico and India demonstrated an average reduction of 43% in IOP from 25.5 mmHg’ pre procedure to 14.6 mmHg’ after 12 months follow-up.
  • In addition, the Company’s procedure reduced the number of medications taken by the treated patients from 2.6 medications to 0.6, on average.
  • These results reflect a Qualified success, (i.e. IOP of less than 18 mmHg’, regardless of medication) of 95% of those treated in the study, and Complete success, (i.e. IOP of less then 18 mmHg’ with no additional medications), of 67%.

Read the full release.

 

 



Comments

Jump down to form below to submit your own comments

4 Responses to “IOPtima Reports Successful Long-Term Results in the Use of its Laser System for Treatment of Glaucoma”

  • We discussed it in the commentary following the ELT writeup, back in March.

  • ari

    actually, one company is advocating using the excimer to do an ab interno trab using the excimer if im not mistaken

  • Just a historical note — Summit Technology tried this with their excimer laser back in the early days of excimer development. It was called PET (partial excimer trabeculoplasty). It also was self-limiting. They abandoned the project.

    Also, note that Ioptima is using a CO2 laser.

    I have tried contacting them several times to find out more about their technology, but they refuse to respond.

    Irv Arons

  • Dr. Weitzner

    i like the idea of no penetrating the ac- hypotony probably much less likely. and the self-stopping technology is sweet. but unfortunately, this is still a bleb-based procedure, so all those problems still bedevil us, namely, late scarring/failure, leaks, infection etc. if this laser is not expensive, it may be nice to have when doing trabs. if expensive, i doubt asc’s buying it when reimbursements keep going down.

    Trackback URL
    http://eyedocnews.com/001092-ioptima-reports-successful-long-term-results-in-the-use-of-its-laser-system-for-treatment-of-glaucoma/trackback/

    Have insights to contribute? Please submit your comment below